Combined hormonal contraception and venous thromboembolism

European Journal of Contraception and Reproductive Health Care

Volumn 12, Issue 2, 2007, Pages 97-106

  Martínez, Francisca ^a   Avecilla, Angels ^b  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b Badalona Serveis Assistencials   (Spain)

Author keywords

Combined hormonal contraceptives; Combined oral contraceptives; Risk factors; Thrombophilia; Venous thromboembolism

Indexed keywords

CHLORMADINONE ACETATE; DESOGESTREL; DIANE; ETHINYLESTRADIOL PLUS ETONOGESTREL; GESTODENE; LEVONORGESTREL; NORETHISTERONE;

ACNE; ALOPECIA; DEEP VEIN THROMBOSIS; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEMOSTASIS; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; HYPERANDROGENISM; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; SEBORRHEA; THROMBOPHILIA;

AGE FACTORS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMANS; NORPREGNENES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 34250173054     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180701300194     Document Type: Review

References (55)

1. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
2. World Health Organization Collaborative Study of Cardiovascular Diseases and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
3. Kemmeren IM, Algra A, Grobee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-7.
4. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1993;353:1167-73.
5. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003;362:185-91.
6. World Health Organization. Cardiovascular disease and use of oral and injectable contraceptives. Contraception 1998;57:315-24.
7. RCOG. Venous thromboembolism and hormonal contraception, Guideline no 40, 2004.
8. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-9.
9. Winkler UH, Schindler AE, Endriket J, Düsterberg B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception 1995;53:75-84.
10. Archer DF, Mammen EF, Grubb GS. The effects of a low-dose monophasic preparation of levonorgestrel and ethinylestradiol on coagulation and other hemostatic factors. Am J Obstet Gynecol 1999;181:S63-6.
11. Bloemenkamp KWM,Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep venous thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet 1995;346:1593-6.
12. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006;73:166-78.
13. Spannagl M, Heinemann LAJ, DoMinh T, et al. Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: A community-based cohort study. Thromb Journal 2005;3:1-10.
14. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35.
15. Hannaford P. The collection and interpretation of epidemiological data about the cardiovascular risks associated with the use of steroid contraceptives. Contraception 1998;57:137-42.
16. Winkler UH. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 2000;62:11S-20S.
17. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999;354:2036-40.
18. Tans G, Van Hylckama A, Thomassen MCLGD, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465-70.
19. Gris JCh, Jamin Ch, Benifla JL, et al. APC resistance and third-generation oral contraceptives. Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease. Hum Reprod 2001;16:3-8.
20. Heinemann LAJ, Kluft C, Spannagl M, Maat MPM. The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception 2002;66:297-304.
21. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482-90.
22. Van RooijenM, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004;190:332-7.
23. van Vliet HA, FrolichM, Christella M, et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005;20:563-8.
24. Jick H, Kaye IA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321:1190-5.
25. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6.
26. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five year national case-control study. Contraception 2002;65:187-96.
27. Farmer RD, Lawrenson RA, Todd IC, et al. A comparison of the risks of venous thromboembolism disease in association with different combined oral contraceptives. Br J Pharmacol 2000;49:580-90.
28. Kenneth A, Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001;135:367-73.
29. Hennessy S, Berlin IA, Kinman IL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2002;64:125-33.
30. Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004;70:3-10.
31. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233-42.
32. Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996;54:5-13.
33. Abrams LS, Skee D, Natarajan J, et al. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 2002;77:S3-12.
34. Smallwood GH, Meador M, Lenihan JP, et al. Efficacy and safety of transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.
35. FDA Updates Labeling for Ortho Evra Contraceptive Patch. FDA Press Release, November 10, 2005. Available at: http://www.fda.gov/bbs/topics/news/ 2005/NEW01262.html.
36. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg ethinyl estradiol. Contraception 2006;73:223-8.
37. Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003;326:257.
38. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Safety 2004;27:1001-18.
39. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427-9.
40. Seaman HE, Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinylestradiol: a nested cohort analysis and case-control study. Hum Reprod 2003;18:522-6.
41. CSM. Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). Curr Probl Pharmacovigilance 2002;28:9-10.
42. Winkler UH, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either 2 mg chlormadinone acetate or 150 mcg desogestrel. Eur J Contracept Reprod Health Care 1999;4:145-54.
43. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest 2002;22:221-31.
44. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen- only contraception in women at high risk of venous thromboembolism. Contraception 2004;70:437-41.
45. The European Agency for the Evaluation of Medicinal Products. CPMP Public assessment report: Combined oral contraceptives and venous thromboembolism. Doc. Ref: EMEA/CPMP/2201/01/en/Final.
46. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives - an approach to specifying rates. Eur J Epidem 2005;20:509-16.
47. Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses Health Study. Ann Intern Med 1994;120:821-6.
48. Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25-year follow up cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999;318:96-100.
49. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Geneva: WHO 2000.
50. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva: WHO 2004.
51. British Society for Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15.
52. Santamaría A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 2001;86:965-71.
53. Vandenbroucke JP, van der Meer F, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptives users in pregnant women? BMJ 1996;313:1127-30.
54. Girolami A, Tormene D, Gavaso S, et al. Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients homozygous and 35 heterozygous. J Thromb Thrombolysis 2004;17:145-9.
55. Nightingale AL, Lawrenson RA, Simpson EL, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5:265-74.